Platelet refractoriness - practical approaches and ongoing dilemmas in patient management

British Journal of Haematology

Volumn 171, Issue 3, 2015, Pages 297-305

  Stanworth, Simon J ^a,b   Navarrete, Cristina ^c   Estcourt, Lise ^a   Marsh, Judith ^d  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b International Collaboration for Transfusion Medicine Guidelines (ICTMG)   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Alloimmunization; Human leucocyte antigen antibodies; Platelet transfusions

Indexed keywords

AMINOCAPROIC ACID; AMPHOTERICIN; BETA1 INTEGRIN; DESMOPRESSIN; GLYCOPROTEIN; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IX; GLYCOPROTEIN V; HEPARIN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA C ANTIGEN; IMMUNOGLOBULIN G; LEUKOCYTE ANTIGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE ANTIGEN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; HLA ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ALLOIMMUNIZATION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; APHERESIS; APLASTIC ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BERNARD SOULIER DISEASE; BLEEDING; BLOOD DONOR; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP TYPING; BLOOD TRANSFUSION REACTION; BODY HEIGHT; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GAMMA IRRADIATION; GLANZMANN DISEASE; HEMOSTASIS; HLA TYPING; HUMAN; HYPOPROLIFERATIVE THROMBOCYTOPENIA; INCIDENCE; LEUKAPHERESIS; LYMPHOCYTOTOXICITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PLASMAPHERESIS; PLATELET REFRACTORINESS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SENSITIZATION; SPLENECTOMY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT GAIN; ADVERSE EFFECTS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; PATHOLOGY; THROMBOCYTE;

BLOOD PLATELETS; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; PLATELET TRANSFUSION;

EID: 84944274683     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13597     Document Type: Review

References (65)

1. Agarwal, N., Chatterjee, K., Sen, A. & Kumar, P. (2014) Prevalence of platelet reactive antibodies in patient's refractory to platelet transfusions. Asian Journal of Transfusion Science, 8, 126-127.
2. Bartholomew, J.R., Salgia, R. & Bell, W.R. (1989) Control of bleeding patients with immune and non-immune thrombocytopenia with aminocaproic acid. Archives of Internal Medicine, 149, 1959-1961.
3. BCSH (2003) British committee for standards in haematology: guidelines for the use of platelet transfusions. British Journal of Haematology, 122, 10-23.
4. Bishop, J.F., McGrath, K., Wolf, M.M., Matthews, J.P., De Luise, T., Holdsworth, R., Yuen, K., Veale, M., Whiteside, M.G. & Cooper, I.A. (1998) Clinical factors influencing the efficacy of pooled platelet transfusions. Blood, 71, 383-387.
5. Bolgiano, D.C., Larson, E.B. & Slichter, S.J. (1989) A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion, 29, 306-310.
6. Bolton-Maggs, P., Chalmers, E., Collins, P., P, H., Kitchen, S., Liesner, R., Minford, A., Mumford, A., Parapia, L., Perry, D., Watson, S., Wilde, J. & Williams, M. (2006) A review of inherited platelet disorders with guidelines for their management on behalf of UKHCDO. British Journal of Haematology, 135, 603-633.
7. Brown, C.J. & Navarrete, C.V. (2011) Clinical relevance of the HLA system in blood transfusion. Vox Sanguinis, 101, 93-105.
8. Curtis, B.R., Edwards, J.T., Hessner, M.J., Klein, J.P. & Aster, R.H. (2000) Blood Group A and B antigens are strongly expressed on platelets of some individuals. Blood, 96, 1574-1581.
9. Daly, P.A., Schiffer, C.A., Aisner, J. & Wiernik, P.H. (1980) One-Hour posttransfusion increments are valuable in predicting the need for HLA-Matched Preparations. JAMA: The Journal of the American Medical Association, 243, 435-438.
10. Delaflor-Weiss, E. & Mintz, P. (2000) The evaluation and management of platelet refractoriness and alloimmunization. Tranfusion Medicine Reviews, 14, 180-196.
11. Doughty, H., Murphy, M., Metcalfe, P., Rohatiner, A., Lister, T. & Waters, A. (1994) Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sanguinis, 66, 200-205.
12. Duquesnoy, R.J. (2008) Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support. Transfusion, 48, 221-227.
13. Dutcher, J., Schiffer, C., Aisner, J. & Wiernik, P. (1981) Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized. Blood, 58, 1007-1011.
14. Fontano-Wendel, R., Silva, L.C., Saviolo, C.B., Primavera, B. & Wendel, S. (2007) Incidence of transfusion induced platelet reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies. Vox Sanguinis, 93, 241-249.
15. Freedman, J., Gafni, A., Garvey, M. & Blanchette, V. (1989) A cost-effectiveness evaluation of platelet crossmatching and HLA matching in the management of alloimmunized thrombocytopenic patients. Transfusion, 29, 201-207.
16. Gardner, F.H. & Helmer, R.E. (1980) Aminocaproic Acid: Use in control of hemorrhage in patients with amegakaryocytic thrombocytopenia. JAMA: The Journal of the American Medical Association, 243, 35-37.
17. Gilson, C.R. & Zimring, J.C. (2012) Alloimmunization to transfused platelets requires priming of CD4 + T cells in the splenic microenvironment in a murine model. Transfusion, 52, 849-859.
18. Godeau, B., Fromont, P., Seror, T., Duedari, N. & Bierling, P. (1992) Platelet alloimmunisation after multiple transfusion: A prospective study of 50 patients. British Journal of Haematology, 81, 395-400.
19. Harrison, J. & Navarrete, C. (2000) Selection of platelet donors and provision of HLA matched platelets. In: Histocompatibility Testing (eds by Bidwell, J. & Navarrete, C.), pp. 379-390. Imperial College Press, London.
20. Hod, E. & Schwartz, J. (2008) Platelet transfusion refractoriness. British Journal of Haematology, 142, 348-360.
21. Julmy, F., Ammann, R.A., Taleghani, B.M., Fontana, S., Hirt, A. & Leibundgut, K. (2009) Transfusion efficacy of ABO major mismatched platelets in children is inferior to that of ABO identical platelets. Transfusion, 49, 21-33.
22. Kekomäki, S., Volin, L., Koistinen, P., Koivunen, E., Koskimies, S., Ruutu, T., Timonen, T. & Kekomäki, R. (1998) Successful treatment of platelet transfusion refractoriness: The use of platelet transfusions matched for both human leukocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunised patients with leukaemia. European Journal of Haematology, 60, 112-118.
23. Kerkhoffs, J., Eikenboom, J., van de Watering, L., van Wordragen-Vlaswinkel, R.J., Wijermans, P. & Brand, A. (2008) The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion, 48, 1959-1965.
24. Kickler, T., Kennedy, S.D. & Braine, H.G. (1990) Alloimmunization to platelet specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion, 30, 622-625.
25. Killick, S.B., Win, N., Marsh, J.C., Kaye, T., Yandle, A., Humphries, C., Knowles, S.M. & Gordon-Smith, E.C. (1997) Pilot study of HLA alloimmunization after transfusion with pre-storage leucodepleted blood products in aplastic anaemia. British Journal of Haematology, 97, 677-684.
26. Kleinman, S., King, M.R., Busch, M.P., Murphy, E.L. & Glynn, S.A., for The National Heart Lung and Blood Institute Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II (2012) The NHLBI Retrovirus Epidemiology Donor Studies (REDS and REDS-II): Twenty years of research to advance blood product safety and availability. Transfusion Medical Reviews, 26, 281-304.
27. Kopko, P.M., Warner, P., Kresie, L. & Pancoska, C. (2015) Methods for the selection of platelet products for alloimmune-refractory patients. Transfusion, 55, 235-244.
28. Kurz, M., Greinix, H., Hocker, P., Kalhs, P., Knöbl, P., Mayr, W.R., Pober, M. & Panzer, S. (1996) Specificities of anti-platelets antibodies in multitransfused patients with hemato-oncological disorders. British Journal of Haematology, 95, 564-569.
29. Laundy, G.J., Bradley, B.A., Rees, B.M., Younie, M. & Hows, J.M. (2004) Incidence and specificity of HLA antibodies in multitransfused patients with acquired aplastic anemia. Transfusion, 44, 814-825.
30. Legler, T., Fischer, I., Dittmann, J., Simson, G., Lynen, R., Humpe, A., Riggert, J., Schleyer, E., Kern, W., Hiddemann, W. & Köhler, M. (1997) Frequency and causes of refractoriness in multiply transfused patients. Annals of Hematology, 74, 185-189.
31. Meehan, K.R., Matias, C.O., Rathore, S.S., Sandler, S.G., Kallich, J., LaBrecque, J., Erder, H. & Schulman, K.A. (2000) Platelet transfusions: Utilization and associated costs in a tertiary care hospital. American Journal of Hematology, 64, 251-256.
32. Meenaghan, M., Judson, P., Yousaf, K., Lewis, L. & Pamphilon, D. (1993) Antibodies to platelet GPs V in polytransfused patients with hematological disease. Vox Sanguinis, 64, 167-170.
33. Moroff, G., Garratty, G., Heal, J.M., MacPherson, B.R., Stroncek, D., Huang, S.T., Ho, W., Petz, L.D., Leach, M.F., Lennon, S.S., Rowe, J.M., Saleh, M.N., Arndt, P., Foley, K., Masel, D. & Postoway, N. (1992) Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion, 32, 633-640.
34. Murphy, M. (2014) Managing the platelet refractory patient. ISBT Science Series, 9, 234-238.
35. Murphy, M. & Waters, A. (1985) Immunological aspects of platelet transfusions. British Journal of Haematology, 60, 409-414.
36. Nahirniak, S., Slichter, S.J., Tanael, S., Rebulla, P., Pavenski, K., Vassalo, R., Fung, M., Duquesnoy, R., Saw, C.L., Stanworth, S., Tinmouth, A., Hume, H., Ponnampalam, A., Moltzan, C., Berry, B. & Shehata, N. (2015) Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia. Transfusin Medicine Reviews, 29, 3-13.
37. Nambiar, A., Duquesnoy, R., Adams, S., Zhao, Y., Oblitas, J., Leitman, S., Stroncek, D. & Marincola, F. (2006) HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood, 107, 1680-1687.
38. Novotny, V.M.J. (1999) Prevention and management of platelet transfusion refractoriness. Vox Sanguinis, 76, 1-13.
39. Patel, S.R., Arthur, C.M., Rodrigues, L., Xue, C., Zimring, J.C., Hendrickson, J.E. & Stowell, S.R. (2014) CD8 + T cells mediate antibody-independent platelet clearance following transfusion. Blood (ASH Annual Meeting Abstracts).124, 21.
40. Pavenski, K., Freedman, J. & Semple, J.W. (2012) HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens, 79, 237-245.
41. Pavenski, K., Rebulla, P., Duquesnoy, R., Saw, C.L., Slichter, S.J., Tanael, S. & Shehata, N., International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies (ICTMG) Collaborators. (2013) Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion, 53, 2230-2242.
42. Pena, J.R., Saidman, S.L., Girouard, T.C., Meister, E., Dzik, W.H. & Makar, R.S. (2014) Anti-HLA alloantibodies in surgical patients refractory to platelet transfusion. American Journal of Hematology, 89, E133-E137.
43. Petz, L.D., Garratty, G., Calhoun, L., Clark, B.D., Terasaki, P.I., Gresens, C., Gornbein, J.A., Landaw, E.M., Smith, R. & Cecka, J.M. (2000) Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion, 40, 1446-1456.
44. Quillen, K., Medrano, C., Adams, S., Peterson, B., Hackett, J., Leitman, S.F., Klein, H.G. & Stoncek, D.F. (2011) Screening plateletpheresis donors for HLA antibodies on two high throughput platforms and correlations with recipient outcome. Transfusion, 51, 504-510.
45. Rachel, J., Summers, T., Sinor, L. & Plapp, F. (1988) Use of a solid phase red blood cell adherence method for pretransfusion compatibility testing. American Journal of Clinical Pathology, 90, 63-68.
46. Read, E.J., Kodis, C., Carter, C.S. & Leitman, S.F. (1988) Viability of platelets following storage in the irradiated state. Transfusion, 28, 446-450.
47. Rebulla, P. (1993) Formulae for the definition of refractoriness to platelet transfusion. Transfusion Medicine, 3, 91-93.
48. Rebulla, P. (2005) A mini-review on platelet refractoriness. Haematologica, 90, 247-253.
49. Rodey, G., Neylan, J., Whelchel, J., Revels, K. & Bray, R. (1994) Epitope specificity of HLA Class I alloantibodies: I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Human Immunology, 39, 272-280.
50. Schiffer, C.A., Hogge, D.E., Aisner, J., Dutcher, J.P., Lee, E.J. & Papenberg, D. (1984) High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood, 64, 937-940.
51. Schiffer, C.A., Anderson, K.C., Bennett, C.L., Bernstein, S., Elting, L.S., Goldsmith, M., Goldstein, M., Hume, H., McCullough, J.J., McIntyre, R.E., Powell, B.L., Rainey, J.M., Rowley, S.D., Rebulla, P., Troner, M.B. & Wagnon, A.H., American Society of Clinical Oncology. (2001) Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1519-1538.
52. Seftel, M.D., Growe, G.H., Petraszko, T., Benny, W.B., Le, A., Lee, C.Y., Spinelli, J.J., Sutherland, H.J., Tsang, P. & Hogge, D.E. (2004) Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood, 103, 333-339.
53. Shehata, N., Tinmouth, A., Naglie, G., Freedman, J. & Wilson, K. (2009) ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion, 49, 2442-2453.
54. Slichter, S.J. (2007) Platelet transfusion therapy. Hematology/oncology Clinics of North America, 21, 697-729.
55. Slichter, S.J., Davis, K., Enright, H., Braine, H., Gernsheimer, T., Kao, K.J., Kickler, T., Lee, E., McFarland, J., McCullough, J., Rodey, G., Schiffer, C.A. & Woodson, R. (2005) Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood, 105, 4106-4114.
56. Stanworth, S., Estcourt, L.J., Llewelyn, C., Murphy, M. & Wood, E.M. for the TOPPS study investigators. (2014) Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a sub-group analysis of a randomized trial. Transfusion, 54, 2385-2393.
57. The Trial to Reduce Alloimmunization to Platelets Study Group (1997) Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. The New England Journal of Medicine, 337, 1861-1869.
58. Toor, A., Choo, S. & Little, J. (2000) Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplantation, 26, 315-320.
59. Tosato, G., Applebaum, F. & Deisseroth, A. (1978) HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood, 52, 846-854.
60. Triulzi, D.J., Assmann, S.F., Strauss, R.G., Ness, P.M., Hess, J.R., Kaufman, R.M., Granger, S. & Slichter, S.J. (2012) The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood, 119, 5553-5562.
61. Vassallo, R.R., Fung, M., Rebulla, P., Duquesnoy, R., Saw, C.L, Slichter, S.J., Tanael, S. & Shehata, N., International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies. (2014) Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion, 54, 1180-1191.
62. Vassalo, R. (2007) New paradigms in the management of alloimmune refractoriness to platelet transfusions. Current Opinion in Hematology, 14, 655-663.
63. Waters, A., Minchinton, R., Bell, R., Ford, J. & Lister, T. (1981) A crossmatching procedure for the selection of donors for alloimminized patients. British Journal of Haematology, 48, 59-68.
64. Wiita, A. & Nambiar, A. (2012) Logtitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes. Transfusion, 52, 2146-2154.
65. Yankee, R., Grumet, F. & Rogentine, G. (1969) The selection of compatible platelet donors for refractory patients by lymphocyte HLA typing. The New England Journal of Medicine, 281, 1208-1212.